Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blinded, Randomized, Placebo-controlled, Multiple-ascending-dose Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia

NCT04972227 is registered in ClinicalTrials.gov with Tisento Therapeutics as lead sponsor.

NCT NCT04972227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04972227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blinded, Randomized, Placebo-controlled, Multiple-ascending-dose Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia
Lead sponsor
Tisento Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
September 10, 2021
Completion date
April 18, 2022
Enrollment
48 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia